Navigation Links
Venaxis Reports on Recent FDA Submission Activities

CASTLE ROCK, Colo., July 16, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, updated on recent activities concerning its U. S. Food and Drug Administration (FDA) submission for the APPY1 Test that was filed in March 2014. The FDA has reviewed the submission, and provided Venaxis with questions and information requests on the submission.      

Venaxis is compiling responses to the FDA's questions and their requests for additional data and information, as well as seeking clarification from the FDA on certain of its requests. Under the FDA's Submission Issue Meeting procedures, we expect a meeting in the upcoming weeks to discuss the items on which we seek clarification.     

Steve Lundy, President and CEO of Venaxis, stated, "We are encouraged by the FDA's responsiveness to our filing and look forward to working collaboratively with the FDA to complete the review process."

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, multi-analyte assay for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  While FDA clearance is being sought, a limited commercial launch for the APPY1 Test is ongoing in select European countries.  For more information, visit

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1 Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-K for the year ended December 31, 2013, filed with the SEC on March 28, 2014.

Venaxis and APPY1 are trademarks of Venaxis, Inc.

Contact – Jed Mahan,; (303) 794-2000 Ext. 255

SOURCE Venaxis, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Venaxis to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
2. Venaxis to Provide Third Quarter 2013 Business Update
3. Venaxis to Present at Three Upcoming Investor Conferences
4. Venaxis to Present at Canaccord Genuity 33rd Annual Growth Conference
5. Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors
6. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
7. Venaxis to Present at 25th Annual ROTH Conference
8. Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
9. Venaxis to Present at 2013 BIO CEO and Investor Conference
10. AspenBio Pharma Changes Company Name to Venaxis, Inc.
11. Johnson & Johnson Reports 2014 Second-Quarter Results:
Post Your Comments:
(Date:11/30/2015)... 2015 ) ... Drugs Market 2015-2019" report to their offering. ... addition of the "Orphan Drugs Market 2015-2019" ... Research and Markets ( ) has announced ... 2015-2019" report to their offering. ...
(Date:11/30/2015)... , November 30, 2015 global cell culture ... US$6.1 bn to US$11.3 bn by 2022 at a CAGR of ... expected to grow from its 2013 value of US$6.1 bn to ... --> Transparency Market Research has announced the release of a ... to the report, titled ,Cell Culture Market - Global Industry Analysis, ...
(Date:11/30/2015)... 30, 2015 Nautilus Medical Inc. today announced ... platform ( ). The release of MatrixRay to ... 2015 (Radiology Society North America) in Chicago ... U.S. --> --> ... access to radiology studies worldwide via a peer-to-peer exchange ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... PartnerTech , a leader in ... since 2008. Gary Bruce, President of PartnerTech North America, currently serves as Director ... amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. He ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
(Date:11/30/2015)... ... 30, 2015 , ... Third Molar SEO , one ... officially launched a sleek, mobile-ready and user-centric redesigned website. , Vivek Srivastava, founder ... outlines the benefits that its SEO services provide to dentists and why Third ...
(Date:11/30/2015)... & Caicos Islands, BWI (PRWEB) , ... December 01, 2015 , ... ... 2015. Recently Caribbean Journal, one of the leading digital news sites highlighting Caribbean ... top reason? The weather. While much of North America shivers under chilly grey ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... networking organization exclusively for professional women, boasting 850,000 members and over 200 operating ...
Breaking Medicine News(10 mins):